<strong>Background:</strong> <span style="font-family:;" "=""><span style="font-family:Verdana;">Percutaneous mitral balloon valvuloplasty is the main</spa...<strong>Background:</strong> <span style="font-family:;" "=""><span style="font-family:Verdana;">Percutaneous mitral balloon valvuloplasty is the main</span><b><span style="font-family:Verdana;"> </span></b><span style="font-family:Verdana;">procedure in mitral stenosis (MS). It can replace surgical commissurotomy in many cases;however, mitral regurgitation (MR) remains the major procedure complication.</span></span><span style="font-family:Verdana;"> </span><b><span style="font-family:Verdana;">Objectives: </span></b><span style="font-family:;" "=""><span style="font-family:Verdana;">This study was conducted to investigate</span><b><span style="font-family:Verdana;"> </span></b><span style="font-family:Verdana;">predictors of MR as a complication following</span><b></b><span style="font-family:Verdana;">percutaneous mitral valvuloplasty (PMV) using multitrack balloon technique.</span></span><span style="font-family:Verdana;"> </span><b><span style="font-family:Verdana;">Methods: </span></b><span style="font-family:;" "=""><span style="font-family:Verdana;">This cohort study was conducted at both Menoufia University Hospital and Mabaret Misr Elkadima Hospital. We enrolled 121 patients with moderate to severe MS who were subjected to</span><b><span style="font-family:Verdana;"> </span></b><span style="font-family:Verdana;">PMV using multitrack balloon technique during the period from October 2017 to October 2019. Transthoracic echocardiographic evaluation was performed for all patients before and after the procedure. Patients who developed severe MR post procedure were compared with other patients to identify important distinction points.</span></span><span style="font-family:Verdana;"> </span><b><span style="font-family:Verdana;">Results: </span></b><span style="font-family:Verdana;">Most patients (N = 109, </span><span style="font-family:;" "=""><span style="font-family:Verdana;">90.1%) developed no/mild MR (group A), whereas 12 (9.9%) patients developed severe MR (group B) after PMV. Those who developed sever展开更多
文摘<strong>Background:</strong> <span style="font-family:;" "=""><span style="font-family:Verdana;">Percutaneous mitral balloon valvuloplasty is the main</span><b><span style="font-family:Verdana;"> </span></b><span style="font-family:Verdana;">procedure in mitral stenosis (MS). It can replace surgical commissurotomy in many cases;however, mitral regurgitation (MR) remains the major procedure complication.</span></span><span style="font-family:Verdana;"> </span><b><span style="font-family:Verdana;">Objectives: </span></b><span style="font-family:;" "=""><span style="font-family:Verdana;">This study was conducted to investigate</span><b><span style="font-family:Verdana;"> </span></b><span style="font-family:Verdana;">predictors of MR as a complication following</span><b></b><span style="font-family:Verdana;">percutaneous mitral valvuloplasty (PMV) using multitrack balloon technique.</span></span><span style="font-family:Verdana;"> </span><b><span style="font-family:Verdana;">Methods: </span></b><span style="font-family:;" "=""><span style="font-family:Verdana;">This cohort study was conducted at both Menoufia University Hospital and Mabaret Misr Elkadima Hospital. We enrolled 121 patients with moderate to severe MS who were subjected to</span><b><span style="font-family:Verdana;"> </span></b><span style="font-family:Verdana;">PMV using multitrack balloon technique during the period from October 2017 to October 2019. Transthoracic echocardiographic evaluation was performed for all patients before and after the procedure. Patients who developed severe MR post procedure were compared with other patients to identify important distinction points.</span></span><span style="font-family:Verdana;"> </span><b><span style="font-family:Verdana;">Results: </span></b><span style="font-family:Verdana;">Most patients (N = 109, </span><span style="font-family:;" "=""><span style="font-family:Verdana;">90.1%) developed no/mild MR (group A), whereas 12 (9.9%) patients developed severe MR (group B) after PMV. Those who developed sever
